FDA Panel Unanimously Backs First New Vaccine Since 2023
An FDA advisory committee voted 9-0 to recommend Moderna's mRNA flu vaccine, marking the panel's first new vaccine endorsement in over three years.
Tag
5 articles
An FDA advisory committee voted 9-0 to recommend Moderna's mRNA flu vaccine, marking the panel's first new vaccine endorsement in over three years.
Moderna's mRNA-1010 flu vaccine triggers broader antibody responses and durable immunity against multiple influenza strains, study finds.
Moderna and Merck's mRNA vaccine reduced melanoma recurrence risk by 49% over five years, offering new hope for advanced skin cancer patients.
A personalized mRNA cancer vaccine from Moderna and Merck reduced melanoma recurrence risk by 49% over five years, marking a major advance.
A personalized mRNA cancer vaccine combined with Keytruda reduced melanoma recurrence risk by 49% over five years, according to new clinical trial data.